Since PFAPA does not confer clinical sequlae (unlike FMF for example which may cause amyloidosis) and is mainly a quality of life problem, the occurrence of inflammatory marker elevation in between episodes was not considered a response criterion. The gene discussed is MEFV; the disease is amyloidosis.